Mylan Inc. has launched atovaquone and proguanil hydrochloride tablets (62.5 mg/25 mg and 250 mg/100 mg), a medication for malaria.


Mylan, atovaquone and proguanil hydrochloride tablets, Malarone, generic version, malaria medication, GlaxoSmithKline






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan releases generic Malarone tablets

May 29th, 2014

PITTSBURGH – Mylan Inc. has launched atovaquone and proguanil hydrochloride tablets (62.5 mg/25 mg and 250 mg/100 mg), a medication for malaria.

The company said Thursday that the product is the generic version of GlaxoSmithKline's Malarone tablets.

According to Mylan, atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of Plasmodium falciparum malaria and the treatment of acute, uncomplicated P. falciparum malaria.

Atovaquone and proguanil hydrochloride tablets (62.5 mg/25 mg and 250 mg/100 mg) had U.S. sales of approximately $89.4 million for the 12 months ended March 31, according to IMS Health data cited by Mylan.

Advertisement